



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Bio

Search PubMed for



Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Sort Save Text Clip Add Order

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

PubMed Services

Journal Browser

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Curr Opin Pharmacol 2001 Jun;1(3):265-71

Related Articles. **NEW Books**
LinkOut

Monoclonal antibodies as a strategy for pulmonary diseases.

Torphy TJ, Li L, Griswold DE.

Centocor Inc., Malvern, PA 19355-1307, USA. torphyt@centocor.com

Monoclonal antibodies have been used successfully to elucidate the roles of putative mediators of pulmonary disease. In particular, clinical trials with monoclonal antibodies directed against interleukin-5, IgE or CD4 yielded results that were critical in dissecting the pathophysiology of asthma; but, more importantly, fundamental changes in the discovery, manufacture and safety of monoclonal antibodies have reinforced the enormous potential of these agents in treating pulmonary diseases. An unprecedented number of monoclonal antibodies are in development for a variety of acute and chronic conditions. Moreover, whereas only two monoclonal antibodies had received regulatory approval from the United States Food and Drug Administration between 1986 and 1997, seven more have received approval since then. Indeed, monoclonal antibody therapy has come of age.

PMID: 11712750 [PubMed - in process]

Display Abstract Sort Save Text Clip Add Order

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

sparc-sun-solaris2 8 Jan 29 2002 15:20:39